These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20868306)

  • 21. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
    Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
    J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
    Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
    Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multiple paths towards MET receptor addiction in cancer.
    Duplaquet L; Kherrouche Z; Baldacci S; Jamme P; Cortot AB; Copin MC; Tulasne D
    Oncogene; 2018 Jun; 37(24):3200-3215. PubMed ID: 29551767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Met tyrosine kinase receptor in development and cancer.
    Gentile A; Trusolino L; Comoglio PM
    Cancer Metastasis Rev; 2008 Mar; 27(1):85-94. PubMed ID: 18175071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MET Oncogene Targeting for Cancer Immunotherapy.
    Lombardi AM; Sangiolo D; Vigna E
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
    Finisguerra V; Prenen H; Mazzone M
    Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invasive growth: a genetic program.
    Gentile A; Comoglio PM
    Int J Dev Biol; 2004; 48(5-6):451-6. PubMed ID: 15349819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of the wild-type and Y1235D mutant Met kinase activation.
    Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
    Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
    Shen A; Wang L; Huang M; Sun J; Chen Y; Shen YY; Yang X; Wang X; Ding J; Geng M
    Cancer Res; 2015 Nov; 75(21):4548-59. PubMed ID: 26483207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
    Di Renzo MF; Olivero M; Martone T; Maffe A; Maggiora P; Stefani AD; Valente G; Giordano S; Cortesina G; Comoglio PM
    Oncogene; 2000 Mar; 19(12):1547-55. PubMed ID: 10734314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
    Gual P; Giordano S; Anguissola S; Comoglio PM
    Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. cMET as a potential therapeutic target in gastric cancer (Review).
    Teng L; Lu J
    Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
    J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.
    Hansel DE; Rahman A; House M; Ashfaq R; Berg K; Yeo CJ; Maitra A
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6152-8. PubMed ID: 15448002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.
    Orlando E; Aebersold DM; Medová M; Zimmer Y
    Cancer Lett; 2019 Feb; 443():189-202. PubMed ID: 30550851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
    Comoglio PM; Trusolino L; Boccaccio C
    Nat Rev Cancer; 2018 Jun; 18(6):341-358. PubMed ID: 29674709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [MET: new target, new combinations].
    Serrate C; Watson S; Vignot S
    Bull Cancer; 2011 Jun; 98(6):689-96. PubMed ID: 21622087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MET mutations in cancers of unknown primary origin (CUPs).
    Stella GM; Benvenuti S; Gramaglia D; Scarpa A; Tomezzoli A; Cassoni P; Senetta R; Venesio T; Pozzi E; Bardelli A; Comoglio PM
    Hum Mutat; 2011 Jan; 32(1):44-50. PubMed ID: 20949619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.